目的循证医学证据显示,原发性结肠癌主要治疗除根治手术外,术后辅助化疗的患者额外生存获益似乎与肿瘤分期相关:在氟尿嘧啶为基础的术后6个月辅助化疗中,Ⅲ期结肠癌(淋巴转移阳性)患者5年生存率可提高10%;但在Ⅱ期患者(淋巴转移阴性)中并无类似有说服力的结果。辅助化疗通常只适用于具有不良预后因素的Ⅱ期患者,包括梗阻、穿 Objective Evidence-based medical evidence shows that in addition to radical surgery for primary colorectal cancer, the additional survival benefit of postoperative adjuvant chemotherapy seems to correlate with tumor stage: in 5-FU adjuvant chemotherapy after 6 months of fluorouracil treatment, III The 5-year survival rate of patients with colon cancer (positive lymph node metastases) can be increased by 10%; however, there is no similarly convincing result in stage II patients (negative lymph node metastases). Adjuvant chemotherapy is usually only suitable for stage II patients with poor prognostic factors, including obstruction and wear